MedTrace Logo

FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma

NCT04625907 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 1672

Last updated 2024-05-23

No results posted yet for this study

Summary

FaR-RMS is an over-arching study for children and adults with newly diagnosed and relapsed rhabdomyosarcoma (RMS)

Conditions

  • Rhabdomyosarcoma

Interventions

DRUG

Irinotecan

antineoplastic enzyme inhibitor

DRUG

Actinomycin D

Antineoplastic agent that is a polypeptide antibiotic

DRUG

Doxorubicin

An anthracycline topoisomerase inhibitor isolated from streptpmyces peucetius var. casesius

DRUG

Ifosfamide

chemotherapeutic agent chemically related to the nitrogen mustards and is a synthetic analog of cyclophosphamide

DRUG

Vincristine

anti neoplastic vinca alkaloid agent

DRUG

Vinorelbine

vinca alkaloid with a role as an antineoplastic agent

DRUG

Cyclophosphamide

Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent

DRUG

Temozolomide

oral antineoplastic alkylating agent

RADIATION

radiotherapy

Ionising radiation

DRUG

Regorafenib

Oral multi-kinase inhibitor that targets a broad range of angiogenic, stromal and oncogenic kinases, including vascular endothelial growth factor receptors (VEFGR) 1, 2 and 3, tyrosine kinase with immunoglobulin and epidermal growth factor homology domain 2 (TIE2), platelet-derived growth factor receptor (PDGFR), fibroblast growth factor receptors (FGFR), c-KIT, RET, RAF-1 and BRAF (wild-type and V600E mutant).

Sponsors & Collaborators

  • University of Birmingham

    lead OTHER

Principal Investigators

  • Meriel Jenney · Chief Investigator

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-09-17
Primary Completion
2030-06-30
Completion
2030-06-30

Countries

  • Australia
  • Austria
  • Belgium
  • Czechia
  • Denmark
  • France
  • Greece
  • Ireland
  • Israel
  • Italy
  • Netherlands
  • New Zealand
  • Norway
  • Portugal
  • Slovakia
  • Slovenia
  • Spain
  • Sweden
  • Switzerland
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04625907 on ClinicalTrials.gov